Amphastar P (AMPH)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	351,121	326,149	276,256	266,874	248,860	233,926	226,599	210,619	199,739	180,337	165,662	151,463	143,340	139,889	138,633	137,843	131,923	133,231	127,239	120,916
Revenue (ttm)	US$ in thousands	644,395	601,313	540,886	518,641	498,987	484,851	476,920	455,116	437,768	412,802	384,035	368,178	349,846	337,308	334,014	327,255	322,357	328,664	324,070	316,063
Gross profit margin		54.49%	54.24%	51.07%	51.46%	49.87%	48.25%	47.51%	46.28%	45.63%	43.69%	43.14%	41.14%	40.97%	41.47%	41.51%	42.12%	40.92%	40.54%	39.26%	38.26%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $351,121K ÷ $644,395K
= 54.49%

The gross profit margin of Amphastar Pharmaceuticals Inc has shown a generally increasing trend over the past eight quarters, reflecting an improvement in the company's ability to generate profit from its core operations. The margin stood at 54.49% in Q4 2023, the highest among the reported quarters, indicating that the company retained a relatively high portion of revenue after accounting for the cost of goods sold. This upward trajectory suggests that Amphastar Pharmaceuticals has been effectively managing its production costs or realizing higher sales prices. Overall, the consistent improvement in gross profit margin reflects positively on the company's operational efficiency and pricing strategies.